Mitofusin-2 Expression Is Implicated in Cervical Cancer Pathogenesis

被引:18
作者
Ahn, Sung Yong [1 ]
Li, Chengri [3 ]
Zhang, Xianglan [4 ]
Hyun, Young-Min [1 ,2 ]
机构
[1] Yonsei Univ, Coll Med, Dept Anat, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Yonsei Univ, Coll Med, PLUS Project Med Sci BK21, Seoul, South Korea
[3] Yonsei Univ, Coll Dent, Oral Canc Res Inst, Seoul, South Korea
[4] Yanbian Univ Hosp, Dept Pathol, Yanji, Peoples R China
基金
新加坡国家研究基金会;
关键词
Mitofusin-2; oncogene; cervical intraepithelial neoplasia; cervical carcinogenesis; cervical cancer pathogenesis; biomarker; SQUAMOUS-CELL CARCINOMA; MITOCHONDRIAL FUSION; PROGNOSTIC MARKER; MFN2; IMMUNOHISTOCHEMISTRY; DYSREGULATION; INHIBITION; ACTIVATION; BIOMARKERS; ANTIGEN;
D O I
10.21873/anticanres.12610
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: It remains unclear whether mitofusin-2 (MFN2) functions as a tumour suppressor or oncogene in cancer progression. In this study we, therefore, aimed to investigate the effect of MFN2 on the pathogenesis of cervical cancer. Materials and Methods: MFN2 expression was detected in seven healthy cervical, 64 cervical intraepithelial neoplasia (CIN), and 120 cervical squamous cell carcinoma (SCC) tissues by immunohistochemistry. Moreover, biological function of MFN2 in cervical cancer was investigated in vitro. Results: MFN2 levels exhibited a tendency to gradually increase from healthy cervical tissue to CIN to SCC. Moreover, MFN2 expression was significantly associated with higher T-stage (p=0.008) and lymph node metastasis (p<0.001). The proliferative, migratory, and invasive abilities of MFN2-knockdown cells were significantly lower (p<0.001, p<0.001, and p<0.001, respectively) than control cells. Conclusion: MFN2 may be involved in cervical cancer pathogenesis as an oncogene and might serve as a biomarker of cervical SCC.
引用
收藏
页码:3419 / 3426
页数:8
相关论文
共 33 条
  • [11] The evaluative value of Sema3C and MFN2 co-expression detected by immunohistochemistry for prognosis in hepatocellular carcinoma patients after hepatectomy
    Feng, Xu
    Zhu, Kelei
    Liu, Jinghua
    Chen, Jiang
    Tang, Jiacheng
    Liang, Yuelong
    Jin, Enan
    Liang, Xiao
    Cai, Xiujun
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 3213 - 3221
  • [12] SPARC Promotes Cathepsin B-Mediated Melanoma Invasiveness through a Collagen I/α2β1 Integrin Axis
    Girotti, Maria R.
    Fernandez, Marisol
    Lopez, Juan A.
    Camafeita, Emilio
    Fernandez, Elmer A.
    Albar, Juan P.
    Benedetti, Lorena G.
    Valacco, Maria P.
    Brekken, Rolf A.
    Podhajcer, Osvaldo L.
    Llera, Andrea S.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (12) : 2438 - 2447
  • [13] Subjects With Early-Onset Type 2 Diabetes Show Defective Activation of the Skeletal Muscle PGC-1α/Mitofusin-2 Regulatory Pathway in Response to Physical Activity
    Isabel Hernandez-Alvarez, Maria
    Thabit, Hood
    Burns, Nicole
    Shah, Syed
    Brema, Imad
    Hatunic, Mensud
    Finucane, Francis
    Liesa, Marc
    Chiellini, Chiara
    Naon, Deborah
    Zorzano, Antonio
    Nolan, John J.
    [J]. DIABETES CARE, 2010, 33 (03) : 645 - 651
  • [14] Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma
    Jin, Baiye
    Fu, Guanghou
    Pan, Hao
    Cheng, Xiaofei
    Zhou, Lin
    Lv, Jia
    Chen, Geming
    Zheng, Shusen
    [J]. MEDICAL ONCOLOGY, 2011, 28 : S373 - S380
  • [15] Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer
    Jung, Hun Soon
    Rajasekaran, Nirmal
    Ju, Woong
    Shin, Young Kee
    [J]. JOURNAL OF CLINICAL MEDICINE, 2015, 4 (05): : 1126 - 1155
  • [16] KAINZ C, 1993, PATHOLOGE, V14, P264
  • [17] Kjaer SK, 2002, BRIT MED J, V325, P572, DOI [10.1136/bmj.325.7364.572, 10.1136/bmj.i2820]
  • [18] Lein M, 2000, INT J CANCER, V85, P801, DOI 10.1002/(SICI)1097-0215(20000315)85:6<801::AID-IJC11>3.0.CO
  • [19] 2-C
  • [20] Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer
    Li, Yi
    Wu, Tao
    Zhang, Beilei
    Yao, Yuanqing
    Yin, Guowu
    [J]. MEDICAL ONCOLOGY, 2012, 29 (05) : 3394 - 3399